Morè Sonia, Offidani Massimo, Corvatta Laura, Petrucci Maria Teresa, Fazio Francesca
Clinica di Ematologia Azienda Ospedaliero, Universitaria delle Marche, 60126 Ancona, Italy.
Unità Operativa Complessa di Medicina, Ospedale Profili, 60044 Fabriano, Italy.
Cancers (Basel). 2023 May 27;15(11):2948. doi: 10.3390/cancers15112948.
Despite the recent approval of novel immunotherapies, such as immunomodulatory drugs, proteasome inhibitors and anti-CD38 monoclonal antibodies, Multiple Myeloma (MM) remains incurable, and the acquisition of triple-refractoriness leads to really dismal outcomes in even earlier lines of therapy. More recently, innovative therapeutic strategies targeting B cell maturation antigen (BCMA), highly expressed on the plasma cell surface, are drawing different future landscapes in terms of effectiveness and outcomes. Belantamab Mafodotin, a first-in-class anti-BCMA antibody-drug conjugate, demonstrated good efficacy and safety profile in triple-refractory patients in the phase 2 DREAMM-2 trial, and it was approved for the treatment of MM triple-exposed patients with >4 prior lines of therapy. Here, starting from Belantamab Mafodotin clinical trials and also exploring combination studies and different schedules in order to improve its efficacy and toxicity, we focused on real-life experiences all over the world, which have confirmed clinical trial data and encourage further Belantamab Mafodotin investigations.
尽管最近新型免疫疗法如免疫调节药物、蛋白酶体抑制剂和抗CD38单克隆抗体已获批准，但多发性骨髓瘤（MM）仍然无法治愈，而获得三重难治性即使在更早的治疗线中也会导致非常糟糕的结果。最近，针对浆细胞表面高表达的B细胞成熟抗原（BCMA）的创新治疗策略在有效性和结果方面描绘了不同的未来前景。贝兰他单抗马福多汀是首个抗BCMA抗体药物偶联物，在2期DREAMM-2试验中，它在三重难治性患者中显示出良好的疗效和安全性，并且被批准用于治疗接受过>4线先前治疗的MM三重暴露患者。在此，从贝兰他单抗马福多汀的临床试验出发，同时探索联合研究和不同给药方案以提高其疗效和毒性，我们关注了世界各地的真实临床经验，这些经验证实了临床试验数据，并鼓励对贝兰他单抗马福多汀进行进一步研究。
